West Pharmaceutical Services (WST) Income from Continuing Operations (2009 - 2026)

West Pharmaceutical Services has disclosed Income from Continuing Operations across 18 years of filings, most recently posting 135400000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 135400000.0, up 56.71% year-over-year; the trailing twelve-month figure through Mar 2026 was 528300000.0 (up 16.52% YoY), and the FY2025 annual result was 479300000.0, changed 0.27% from the prior year.
• Income from Continuing Operations came in at 135400000.0 for Q1 2026 at West Pharmaceutical Services, up from 128200000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 183000000.0 in Q2 2022 to a low of 86400000.0 in Q1 2025.
• The 5-year median for Income from Continuing Operations is 132100000.0 (2024), against an average of 131388235.29.
• Across the five-year window, Income from Continuing Operations tumbled 32.43% in 2022 and jumped 56.71% in 2026, its largest moves.
• West Pharmaceutical Services' Income from Continuing Operations stood at 99800000.0 in 2022, then jumped by 33.97% to 133700000.0 in 2023, then slipped by 4.19% to 128100000.0 in 2024, then grew by 0.08% to 128200000.0 in 2025, then increased by 5.62% to 135400000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 135400000.0 (Q1 2026), 128200000.0 (Q4 2025), and 137900000.0 (Q3 2025), per Business Quant data.